June 2025
1. DISANTO G, Sacco R, Mallucci G, Zecca C, et al
   Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple Sclerosis.
   Ann Neurol. 2025 Jun 11. doi: 10.1002/ana.27281.
   

   >> Share

   
   
2. SABATINO JJ JR, Cree BAC, Hauser SL
   New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
   Ann Neurol. 2025 Jun 6. doi: 10.1002/ana.27270.
   

   >> Share

   
   April 2025
3. POOLE S, Sisodia N, Koshal K, Henderson K, et al
   Detecting New Lesions Using a Large Language Model: Applications in Real-World Multiple Sclerosis Datasets.
   Ann Neurol. 2025 Apr 25. doi: 10.1002/ana.27251.
   

   >> Share

   
   
4. MURARO PA, Zito A, Signori A, Sormani MP, et al
   Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.
   Ann Neurol. 2025 Apr 19. doi: 10.1002/ana.27247.
   

   >> Share

   
   
5. PANSIERI J, Pisa M, Yee S, Gutnikova A, et al
   Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex.
   Ann Neurol. 2025 Apr 8. doi: 10.1002/ana.27231.
   

   >> Share

   
   February 2025
6. GUO K, Peng F, Liu J, Long Y, et al
   Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study.
   Ann Neurol. 2025 Feb 24. doi: 10.1002/ana.27218.
   

   >> Share

   
   
7. ABBADESSA G, Nagano A, Hametner S, Howell O, et al
   Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and Network Analysis of White Matter Pathology Transcriptomics.
   Ann Neurol. 2025 Feb 14. doi: 10.1002/ana.27216.
   

   >> Share

   
   
8. HASHEMI E, Srivastava IN, Aguirre A, Yoseph ET, et al
   A Novel Mouse Model for Cerebral Inflammatory Demyelination in X-Linked Adrenoleukodystrophy: Insights into Pathogenesis and Potential Therapeutic Targets.
   Ann Neurol. 2025;97:296-312.
   

   >> Share

   
   
9. PAPADOPOULOS D, Magliozzi R, Bandiera S, Cimignolo I, et al
   Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study.
   Ann Neurol. 2025 Feb 1. doi: 10.1002/ana.27195.
   

   >> Share

   
   January 2025
10. MARGONI M, Storelli L, Pagani E, Preziosa P, et al
    Subventricular Zone Microstructure in Pediatric-Onset Multiple Sclerosis.
    Ann Neurol. 2025 Jan 18. doi: 10.1002/ana.27180.
    

    >> Share

    
    December 2024
11. BRIER MR, Judge B, Ying C, Salter A, et al
    Increased White Matter Aerobic Glycolysis in Multiple Sclerosis.
    Ann Neurol. 2024 Dec 23. doi: 10.1002/ana.27165.
    

    >> Share

    
    
12. HELBIG I, Ganesan S
    NORSE, FIRES, and a Polygenic Trickle of Autoimmunity.
    Ann Neurol. 2024 Dec 7. doi: 10.1002/ana.27148.
    

    >> Share

    
    November 2024
13. BROWNLEE WJ, Vidal-Jordana A, Shatila M, Strijbis E, et al
    Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
    Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145.
    

    >> Share

    
    
14. CABALLERO-AVILA M, Martin-Aguilar L, Pascual-Goni E, Michael MR, et al
    Long-Term Follow Up in Anti-Contactin-1 Autoimmune Nodopathy.
    Ann Neurol. 2024 Nov 27. doi: 10.1002/ana.27142.
    

    >> Share

    
    
15. PROTOPAPA M, Steffen F, Schraad M, Ruck T, et al
    Increased Disability Progression in rs10191329(AA) Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
    Ann Neurol. 2024 Nov 26. doi: 10.1002/ana.27144.
    

    >> Share

    
    
16. MEUTH SG, Wolff S, Muck A, Willison A, et al
    Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
    Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143.
    

    >> Share

    
    October 2024
17. WANG W, Yin J
    Coexistence of Acute Cerebral Infarction and Reversible Posterior Encephalopathy Syndrome in a Patient with Hashimoto's Thyroiditis.
    Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27120.
    

    >> Share

    
    
18. JANG Y, Hong SE, Ahn SH, Mon SY, et al
    Polygenic Landscape of Cryptogenic New-Onset Refractory Status Epilepticus: A Comprehensive Whole-Genome Sequencing Study.
    Ann Neurol. 2024 Oct 23. doi: 10.1002/ana.27100.
    

    >> Share

    
    
19. ALZAMANAN F, Ding Y, Harroud A
    Obesity and Multiple Sclerosis Severity: A Mendelian Randomization Study.
    Ann Neurol. 2024 Oct 21. doi: 10.1002/ana.27112.
    

    >> Share

    
    
20. MESSMER ML, Salapa HE, Popescu BF, Levin MC, et al
    RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to Neurodegeneration in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 18. doi: 10.1002/ana.27114.
    

    >> Share

    
    
21. BENKERT P, Maleska Maceski A, Schaedelin S, Oechtering J, et al
    Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096.
    

    >> Share

    
    
22. SANABRIA-DIAZ G, Cagol A, Lu PJ, Barakovic M, et al
    Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 10. doi: 10.1002/ana.27102.
    

    >> Share

    
    
23. MONTOBBIO N, Cordioli C, Signori A, Bovis F, et al
    Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.
    Ann Neurol. 2024 Oct 9. doi: 10.1002/ana.27093.
    

    >> Share

    
    
24. SUZUKI S, Utsugisawa K
    MuSK-Myasthenia Gravis and Cancer.
    Ann Neurol. 2024 Oct 8. doi: 10.1002/ana.27094.
    

    >> Share

    
    
25. FALSO S, Iorio R
    Reply to "MuSK-Myasthenia Gravis and Cancer".
    Ann Neurol. 2024 Oct 4. doi: 10.1002/ana.27091.
    

    >> Share

    
    September 2024
26. FADDA G, Banwell B, Elliott C, Fetco D, et al
    Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.
    Ann Neurol. 2024 Sep 7. doi: 10.1002/ana.27066.
    

    >> Share

    
    August 2024
27. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
    Ann Neurol. 2024;96:302-305.
    

    >> Share

    
    July 2024
28. MARRODAN M, Calandri IL, Bocancea DI, Ysrraelit MC, et al
    Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.
    Ann Neurol. 2024 Jul 26. doi: 10.1002/ana.27043.
    

    >> Share

    
    
29. SCALFARI A, Traboulsee A, Oh J, Airas L, et al
    Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
    Ann Neurol. 2024 Jul 25. doi: 10.1002/ana.27034.
    

    >> Share

    
    
30. FALSO S, Gessi M, Marini S, Benvenuto R, et al
    Cancer Frequency in MuSK Myasthenia Gravis and Histological Evidence of Paraneoplastic Etiology.
    Ann Neurol. 2024 Jul 15. doi: 10.1002/ana.27033.
    

    >> Share

    
    
31. HU Y, Frisell T, Alping P, Song H, et al
    Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
    

    >> Share

    
    
32. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    

    >> Share

    
    
33. GUO A, Zhang Z, Dong GH, Su L, et al
    Cortical Microhemorrhage Presentation of Small Vessel Primary Angiitis of the Central Nervous System.
    Ann Neurol. 2024;96:194-203.
    

    >> Share

    
    June 2024
34. PIEHL F, Alping P, Virtanen S, Englund S, et al
    COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012.
    

    >> Share

    
    May 2024
35. CORTESE R, Battaglini M, Prados F, Gentile G, et al
    Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
    

    >> Share

    
    
36. GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al
    DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959.
    

    >> Share

    
    April 2024
37. GILLIGAN M, Lesnick CE, Guo Y, Bradshaw MJ, et al
    Paraneoplastic Calmodulin Kinase-Like Vesicle-Associated Protein (CAMKV) Autoimmune Encephalitis.
    Ann Neurol. 2024 Apr 18. doi: 10.1002/ana.26943.
    

    >> Share

    
    
38. CALABRESE M, Preziosa P, Scalfari A, Colato E, et al
    Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.
    Ann Neurol. 2024 Apr 3. doi: 10.1002/ana.26913.
    

    >> Share

    
    March 2024
39. NEIDHART S, Vlad B, Hilty M, Hogelin KA, et al
    HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis.
    Ann Neurol. 2024 Mar 29. doi: 10.1002/ana.26921.
    

    >> Share

    
    
40. ALPING P, Neovius M, Piehl F, Frisell T, et al
    Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
    Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914.
    

    >> Share

    
    
41. MARGONI M, Pagani E, Meani A, Preziosa P, et al
    Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric Multiple Sclerosis.
    Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911.
    

    >> Share

    
    February 2024
42. FADDA G, Yea C, O'Mahony J, Waters P, et al
    Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
    Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890.
    

    >> Share

    
    
43. SHU Y, Huang R, Li Q, Lu Y, et al
    Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy Is Associated with HLA-A*3303 and HLA-DPB1*0501.
    Ann Neurol. 2024 Feb 24. doi: 10.1002/ana.26899.
    

    >> Share

    
    
44. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    

    >> Share

    
    December 2023
45. NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al
    High levels of perivascular inflammation and active demyelinating lesions at time of death associated with rapidly progressive multiple sclerosis disease course: a retrospective post-mortem cohort study.
    Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870.
    

    >> Share

    
    
46. MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al
    Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
    Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840.
    

    >> Share

    
    
47. KIM S, Eun MY, Lee JJ, Seok HY, et al
    Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859.
    

    >> Share

    
    
48. DUCHOW A, Bellmann-Strobl J, Friede T, Aktas O, et al
    Time to disability milestones and annualized relapse rates in NMOSD and MOGAD.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26858.
    

    >> Share

    
    
49. VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A
    Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions".
    Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856.
    

    >> Share

    
    
50. KNOWLES S, Middleton R, Cooze B, Farkas I, et al
    Comparing the pathology, clinical and demographic characteristics of younger and older-onset multiple sclerosis.
    Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843.
    

    >> Share

    
    November 2023
51. KREFT KL, Uzochukwu E, Loveless S, Willis M, et al
    Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort.
    Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831.
    

    >> Share

    
    October 2023
52. MAJED M, Valencia Sanchez C, Bennett JL, Fryer J, et al
    Alterations in Aquaporin-4-IgG Serostatus in 986 Patients: A Laboratory-Based Longitudinal Analysis.
    Ann Neurol. 2023;94:727-735.
    

    >> Share

    
    September 2023
53. GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al
    A genetic risk variant for multiple sclerosis severity is associated with brain atrophy.
    Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807.
    

    >> Share

    
    
54. VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al
    MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis.
    Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share